Savara company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

savarapharma.com

Founded Year

2007

Stage

Reverse Merger | IPO

Total Raised

$61.15M

About Savara

Savara (NASDAQ: SVRA) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases.

Savara Headquarter Location

6836 Bee Cave Road Building 3, Suite 200

Austin, Texas, 78746,

United States

888-302-4876

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Savara

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Savara is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Savara Patents

Savara has filed 3 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Medical treatments
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/9/2019

2/18/2020

Dosage forms, Drug delivery devices, Routes of administration, Medical treatments, Pharmacokinetics

Grant

Application Date

8/9/2019

Grant Date

2/18/2020

Title

Related Topics

Dosage forms, Drug delivery devices, Routes of administration, Medical treatments, Pharmacokinetics

Status

Grant

Latest Savara News

Savara to Present at H.C. Wainwright Global Investment Conference

May 17, 2022

May 17, 2022 04:05 PM Eastern Daylight Time AUSTIN, Texas--( BUSINESS WIRE )-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright Global Investment Conference on May 24, 2022 at 4:00 pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com . (Twitter: @SavaraPharma , LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/ ). Contacts

Savara Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Savara Rank

  • When was Savara founded?

    Savara was founded in 2007.

  • Where is Savara's headquarters?

    Savara's headquarters is located at 6836 Bee Cave Road, Austin.

  • What is Savara's latest funding round?

    Savara's latest funding round is Reverse Merger.

  • How much did Savara raise?

    Savara raised a total of $61.15M.

  • Who are Savara's competitors?

    Competitors of Savara include Erydel, MonoSol Rx, Critical Pharmaceuticals, Transcept Pharmaceuticals, OctoPlus and 12 more.

You May Also Like

C
Core Tech Solutions

Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.

T
Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

B
Brainsgate

BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)

E
Erydel

EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

M
MAD Nanolayers

MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.

M
MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.